CorMedix Initiates Share Repurchase Plan Amid Strong Financial Outlook

CorMedix is taking decisive steps to enhance shareholder value, supported by robust preliminary financial results for 2025. The company's strategic direction is now underscored by a newly authorized share repurchase initiative and the recent integration of Melinta Therapeutics, which has significantly expanded its commercial footprint. A key question for investors is whether this operational strength can support expectations for upcoming clinical data milestones.

Preliminary, unaudited figures for the full year 2025 indicate a substantial revenue increase. CorMedix generated approximately $127 million in sales during the fourth quarter alone, bringing the annual total to roughly $310 million. The acquisition of Melinta Therapeutics, finalized in August, has been a major growth driver. On a pro-forma basis, including Melinta's contributions, the combined annual revenue reaches about $400 million.

Operational efficiency remains a highlight. For the final quarter of 2025, the company anticipates an adjusted EBITDA ranging between $77 million and $81 million. This performance demonstrates the immediate accretive effect of integrating Melinta's anti-infective product portfolio.

Share Buyback Program Authorized

In a move to return capital to shareholders, the Board of Directors has approved a repurchase program this week. The authorization permits the company to buy back up to $75 million worth of its own common stock. This program is set to run through the end of 2027, with management intending to commence purchases as early as the first quarter of 2026.

Should investors sell immediately? Or is it worth buying CorMedix?

The buyback will be funded from existing cash reserves. CorMedix ended the year with a strong cash position of approximately $150 million, providing ample flexibility to execute the repurchase while maintaining strategic resources for future investments.

Upcoming Catalysts: Analyst Day and Clinical Data

Market attention is now turning to the company's Analyst Day scheduled for Tuesday, February 10. During this event, management is expected to provide detailed insights into the market potential of its core assets, primarily DefenCath for parenteral nutrition and the drug candidate REZZAYO.

The primary catalyst for the stock in the coming months, however, will be clinical development progress. Top-line data from the Phase III study for REZZAYO is anticipated in the second quarter of 2026. Before that, investors can expect the final, audited financial results for 2025 to be released on March 24.